Macrilen is a growth hormone (GH) secretagogue receptor agonist initially approved by the FDA in 2017. It is indicated for the diagnosis of adult growth hormone deficiency (AGHD) and is the first and only FDA-approved oral test for AGHD diagnosis. The efficacy of Macrilen was established in a randomized, open-label, single-dose, cross-over study. Macrilen was compared to the insulin tolerance test (ITT) in a head to head trial with 140 adults where the overall diagnostic accuracy of Macrilen was comparable to the ITT.

Macrilen (macimorelin) will be considered for coverage when the following criteria are met:

**Diagnostic Use for Growth Hormone Deficiency**

For **initial** authorization:
1. Member is age 18 years or older;
2. Medication must be prescribed by an endocrinologist;
3. Member’s weight is documented on chart notes and member’s BMI is ≤ 40 kg/m^2;; AND
4. Member must have documentation of a contraindication or intolerance to **both** the insulin tolerance test and glucagon stimulation test.
5. **Dosage allowed/Quantity limit:** 0.5 mg/kg as single dose.
   - Quantity Limit: 1 pouch for weight ≤ 120 kg
   - 2 pouches for weight >120 kg

*If all the above requirements are met, the medication will be approved for 30 days and will not be reauthorized.*

CareSource considers Macrilen (macimorelin) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

### References:


Effective date: 04/01/2023
Revised date: 11/08/2022